CytRx Corporation (CYTR)
| Previous close | 0.6600 |
| Open | 0.6600 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's range | 0.6300 - 0.6850 |
| 52-week range | 0.2100 - 0.8500 |
| Volume | 36,881 |
| Avg. volume | 62,657 |
| Market cap | 24.077M |
| Beta (5Y monthly) | 1.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2090 |
| Earnings date | 09 Nov 2018 - 12 Nov 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S ("Orphazyme") announced that the U.S. Food and Drug Administration ("FDA") has accepted, with Priority Review, the company’s New Drug Application ("NDA") for arimoclomol for the treatment of Niemann-Pick disease Type C ("NPC").
- Business Wire
CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced voting results from the Company’s Annual Meeting of Stockholders (the "Annual Meeting") that was held earlier today. Stockholders voted to re-elect Steven A. Kriegsman, CytRx’s Chairman and Chief Executive Officer, and Dr. Louis Ignarro, CytRx’s Lead Director, to the Board of Directors (the "Board").
- Business Wire
CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it is taking several steps to strengthen the Company’s corporate governance and support its strategic priorities, including its previously stated focus on achieving operational efficiencies and preserving capital. CytRx also announced that it has reached an agreement with stockholder Jerald A. Hammann, who will withdraw his notice of nomination and not stand for election to the Board of Directors (the "Board") at the Company’s 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") that is scheduled for September 3, 2020. The details included in the agreement can be found in the Current Report on Form 8-K that CytRx will file with the Securities and Exchange Commission.
